

Highlights of This Issue 1023

SMALL MOLECULE THERAPEUTICS

1025 LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma

Linlin Yang, Bhavna Kumar, Changxian Shen, Songzhu Zhao, Dukagjin Blakaj, Tianyun Li, Mitchell Romito, Theodoros N. Teknos, and Terence M. Williams

1036 SF2523: Dual PI3K/BRD4 Inhibitor Blocks Tumor Immunosuppression and Promotes Adaptive Immune Responses in Cancer

Shweta Joshi, Alok R. Singh, Kevin X. Liu, Timothy V. Pham, Muamera Zulcic, Dylan Skola, Hyun Bae Chun, Christopher K. Glass, Guillermo A. Morales, Joseph R. Garlich, and Donald L. Durden

1045 Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma

Yang Yu, Yanling Zhao, Yihui Fan, Zhenghu Chen, Hui Li, Jiaxiong Lu, Kevin Guo, Sarah E. Woodfield, Sanjeev A. Vasudevan, Jianhua Yang, and Jed G. Nuchtern

1057 Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, and Daniela Matei

LARGE MOLECULE THERAPEUTICS

1069 A Tumor-Peptide–Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy

Carolin Heße, Sebastian Kollenda, Olga Rotan, Eva Pastille, Alexandra Adamczyk, Christina Wenzek, Wiebke Hansen, Matthias Epple, Jan Buer, Astrid M. Westendorf, and Torben Knuschke

1081 A Rationally Designed Peptide Antagonist of the PD-1 Signaling Pathway as an Immunomodulatory Agent for Cancer Therapy

Pottayil G. Sasikumar, Raghuvveer K. Ramachandra, Srinivas Adurthi, Amit A. Dhudashiya, Sureshkumar Vadlamani, Koteswararao Vemula, Sriharibabu Vunnum, Leena K. Satyam, Dodderi S. Samiulla, Krishnaprasad Subbarao, Rashmi Nair, Rajeev Shrimali, Nagaraj Gowda, and Murali Ramachandra

1092 Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design

Nam-Kyung Lee, Yang Su, Scott Bidlingmaier, and Bin Liu

1104 Discovery of A Novel EGFR-Targeting Antibody–Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies

Kaijie He, Jianyan Xu, Jindong Liang, Jiahua Jiang, Mi Tang, Xin Ye, Zhebin Zhang, Lei Zhang, Beibei Fu, Yan Li, Chang Bai, Lianshan Zhang, and Weikang Tao

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

1115 Neutralization of BCL-2/X_L Enhances the Cytotoxicity of T-DM1 *In Vivo*

Jason J. Zoeller, Aleksandr Vagodny, Krishan Taneja, Benjamin Y. Tan, Neil O'Brien, Dennis J. Slamon, Deepak Sampath, Joel D. Levenson, Roderick T. Bronson, Deborah A. Dillon, and Joan S. Brugge

1127 Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β 1 Blocking Antibody OS2966

Tae Jin Lee, Mitra Nair, Yeshavanth Banasavadi-Siddegowda, Joseph Liu, Tejaswini Nallanagulari, Alena Cristina Jaime-Ramirez, Jeffrey Yunhua Guo, Haroon Quadri, Jianying Zhang, Kurt H. Bockhorst, Manish K. Aghi, W. Shawn Carbonell, Balveen Kaur, and Ji Young Yoo

Table of Contents

- 1137** **Functional Analysis of Somatic Mutations Affecting Receptor Tyrosine Kinase Family in Metastatic Colorectal Cancer**
Leslie Duplaquet, Martin Figeac, Frédéric Leprêtre, Charline Frandemiche, Céline Villenet, Shéhérazade Sebda, Nasrin Sarafan-Vasseur, Mélanie Bénézoène, Audrey Vincent, Gautier Goormachtigh, Laurence Wicquart, Nathalie Rousseau, Ludivine Beaussire, Stéphanie Truant, Pierre Michel, Jean-Christophe Sabourin, Françoise Galateau-Sallé, Marie-Christine Copin, Gérard Zalcman, Yvan De Launoit, Véronique Fafeur, and David Tulasne

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 1149** **Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis**
Filip Janku, Eli L. Diamond, Aaron M. Goodman, Vaijayanthi Kandadai Raghavan, Tamara G. Barnes, Shumei Kato, Omar Abdel-Wahab, Benjamin H. Durham, Funda Meric-Bernstam, and Razelle Kurzrock
- 1158** **Genotyping of Circulating Tumor DNA Reveals the Clinically Actionable Mutation Landscape of Advanced Colorectal Cancer**
Weiguo Cao, Yaping Xu, Lianpeng Chang, Yuhua Gong, Liren Li, Xianwei Mo, Xin Zhang, Guole Lin, Jiaolin Zhou, Dan Liu, Yuting Yi, Pingping Dai, Chenchen Zhu, Tao Liu, Yuxing Chu, Yanfang Guan, Yongsheng Chen, Jiayin Wang, Xuefeng Xia, Ling Yang, Xin Yi, and Yong Cheng

MODELS AND TECHNOLOGIES

- 1168** **Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing**
Jasmien Cornillie, Agnieszka Wozniak, Haifu Li, Yannick Wang, Bram Boeckx, Yemarsht K. Gebreyohannes, Jasmien Wellens, Ulla Vanleeuw, Daphne Hompes, Marguerite Stas, Friedl Sinnaeve, Hazem Wafa, Diether Lambrechts, Maria Debiec-Rychter, Raf Sciot, and Patrick Schöffski

RETRACTIONS

- 1179** **Retraction: Carfilzomib Interacts Synergistically with Histone Deacetylase Inhibitors in Mantle Cell Lymphoma Cells *In Vitro* and *In Vivo***
Girija Dasmahapatra, Dmitry Lembersky, Minkyong P. Son, Elisa Attkisson, Paul Dent, Richard I. Fisher, Jonathan W. Friedberg, and Steven Grant
- 1180** **Retraction: Obatoclox Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells *In Vitro* and *In Vivo***
Girija Dasmahapatra, Dmitry Lembersky, Minkyong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent, and Steven Grant
- 1181** **Retraction: *In Vitro* and *In Vivo* Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells**
Girija Dasmahapatra, Hiral Patel, Johnathan Friedberg, Steven N. Quayle, Simon S. Jones, and Steven Grant




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

The BCL-2/ X_L pro-survival proteins compromise the effectiveness of cancer therapies. Here, Zoeller and colleagues provide *in vivo* evidence that neutralization of BCL-2/ X_L via navitoclax/ABT-263 enhances the cytotoxic effectiveness of the HER2-targeted antibody-drug conjugate T-DM1. To assess the pathological responses associated with combined treatments, the authors performed specialized histological staining. The cover represents microscopic analysis of a Masson's trichrome stained patient-derived xenograft treated with T-DM1 and navitoclax/ABT-263, and demonstrates substantial elimination of the tumor cells (red) and the emergence of a reactive stroma (blue). For more information, please see the article starting on page 1115.



Molecular Cancer Therapeutics

18 (6)

Mol Cancer Ther 2019;18:1023-1181.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.